CTABF - Canntab granted patent for immediate release cannabidiol formulation tablets

Canntab Therapeutics ([[CTABF]]) announces that the Canadian Intellectual Property Office has allowed Canadian Patent No. CA 3050150 to Canntab, related to its proprietary cannabidiol formulations.The company has filed more than a dozen patent applications in the United States and Canada for which two have now been granted or allowed. The term of the new patent expires on January 22, 2038.Canntab believes its hard pill formulations are superior to other medical CBD and THC delivery systems.

For further details see:

Canntab granted patent for immediate release cannabidiol formulation tablets